ArticlePLoS neglected tropical diseases2021
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.
Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- A model based on meta-analysis to evaluate poor prognosis of patients with severe fever with thrombocytopenia syndrome.Frontiers in microbiology · 2023Pooled it
- Clinical laboratory parameters and fatality of Severe fever with thrombocytopenia syndrome patients: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Ruxolitinib plus standard of care in severe hospitalized adults with severe fever with thrombocytopenia syndrome (SFTS): an exploratory, single-arm trial.BMC medicine · 2024Trial
- Development and validation of a nomogram for predicting 30-day mortality in DBV-induced sepsis with pancreatic injury.iScience · 2026Article
- A 56-Year-Old Male Farmer From China With Severe Fever With Thrombocytopenia Syndrome and Pulmonary Aspergillosis: A Case Report and Review of Literature.The American journal of case reports · 2026Review
- CT-detected lymphadenopathy and prognostic markers in severe fever with thrombocytopenia syndrome: a retrospective study.BMC infectious diseases · 2026Article
- Severe Fever With Thrombocytopenia Syndrome in Korea: Assessing the Impact of Hospital Patient Volume on Care Quality and Policy Implications.Journal of Korean medical science · 2026Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- Standardized LDH-to-lymphocyte ratio improves early mortality prediction in severe fever with thrombocytopenia syndrome: A 15-day competing-risk bedside model.PLoS neglected tropical diseases · 2026Article
- Evaluation of clinical efficacy and safety of T-705 (Favipiravir) in the treatment of fever with thrombocytopenia syndrome: a propensity score matching study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
- Antibody engineering for SFTS treatment: frontier progress and translational challenges.Frontiers in microbiology · 2026Review
- Efficacy of favipiravir treatment for patients with severe fever with thrombocytopenia syndrome assessed with a historical control.Antimicrobial agents and chemotherapy · 2025Observational
- Comprehensive epidemiological analysis of severe fever with thrombocytopenia syndrome in Japan, 2013-2023: descriptive observational study.The Lancet regional health. Western Pacific · 2025Article
- Six recent cases of severe fever with thrombocytopenia syndrome during the 2024 - 2025 in Kochi, Japan: A possible surge and clinical clue for early recognition.IJID regions · 2025Article
- Sustained humoral immunity in the patients recovered from severe fever with thrombocytopenia syndrome.Tropical medicine and health · 2025Article
- Recent Advances in Therapeutics for Severe Fever with Thrombocytopenia Syndrome Virus.Viruses · 2025Review
- Re-evaluating a single-arm trial of favipiravir for severe fever with thrombocytopenia syndrome in Japan: A proposal to use real-world data as external controls.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 16 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7-14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.